NEW YORK ( TheStreet) -- Transition Therapeutics (Nasdaq: TTHI) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has experienced relatively poor performance when compared with the S&P 500 during the past year. Transition Therapeutics Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications primarily in Canada. Transition has a market cap of $49.7 million and is part of the health care sector and drugs industry. Shares are up 46.4% year to date as of the close of trading on Tuesday.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Markets
Replay: Jim Cramer on Earnings Season, China and Amazon Prime Day
Jim Cramer's breaking down what he expects from earnings season, China's slowing growth, and Amazon's Prime day sale.
Dow, S&P 500 and Nasdaq End at Record Closes as Earnings Season Kicks Off
All three stock indexes struggled to a record close Monday as investors gear up for earnings season.
Newt Gingrich on the U.S.-China Trade Talks, Biotech and Advice for Investors
Newt Gingrich weighs in on the U.S.-China trade deal, President Trump's social media presence, his focus on gene therapy and his advice for investors.
JPMorgan Is Bullish on the S&P 500's Second-Half Performance
JPMorgan raised its S&P price target to 3,200 from 3,000.